non-Medicare Advantage business; or other changes in the governmental 
      programs in which Humana participates. Changes to the risk-adjustment 
      model utilized by CMS to adjust premiums paid to Medicare Advantage plans 
      or retrospective recovery by CMS of previously paid premiums as a result 
      of the final rule related to the risk adjustment data validation audit 
      methodology published by CMS on January 30, 2023 (Final RADV Rule), which 
      Humana believes fails to address adequately the statutory requirement of 
      actuarial equivalence and violates the Administrative Procedure Act due 
      to its failure to include a "Fee for Service Adjuster" could have a 
      material adverse effect on the company's operating results, financial 
      position and cash flows. 
 
 
   -- 
 Humana's business activities are subject to substantial government 
      regulation. New laws or regulations, or legislative, judicial, or 
      regulatory changes in existing laws or regulations or their manner of 
      application could increase the company's cost of doing business and have 
      a material adverse effect on Humana's results of operations (including 
      restricting revenue, enrollment and premium growth in certain products 
      and market segments, restricting the company's ability to expand into new 
      markets, increasing the company's medical and operating costs by, among 
      other things, requiring a minimum benefit ratio on insured products, 
      lowering the company's Medicare payment rates and increasing the 
      company's expenses associated with a non-deductible health insurance 
      industry fee and other assessments); the company's financial position 
      (including the company's ability to maintain the value of its goodwill); 
      and the company's cash flows. 
 
 
   -- 
 Humana's failure to manage acquisitions, divestitures and other 
      significant transactions successfully may have a material adverse effect 
      on the company's results of operations, financial position, and cash 
      flows. 
 
 
   -- 
 If Humana fails to develop and maintain satisfactory relationships with 
      the providers of care to its members, the company's business may be 
      adversely affected. 
 
 
   -- 
 Humana faces significant competition in attracting and retaining 
      talented employees. Further, managing succession for, and retention of, 
      key executives is critical to the Company's success, and its failure to 
      do so could adversely affect the Company's businesses, operating results 
      and/or future performance. 
 
 
   -- 
 Humana's pharmacy business is highly competitive and subjects it to 
      regulations and supply chain risks in addition to those the company faces 
      with its core health benefits businesses. 
 
 
   -- 
 Changes in the prescription drug industry pricing benchmarks may 
      adversely affect Humana's financial performance. 
 
 
   -- 
 Humana's ability to obtain funds from certain of its licensed 
      subsidiaries is restricted by state insurance regulations. 
 
 
   -- 
 Downgrades in Humana's debt ratings, should they occur, may adversely 
      affect its business, results of operations, and financial condition. 
 
 
   -- 
 Volatility or disruption in the securities and credit markets may 
      significantly and adversely affect the value of our investment portfolio 
      and the investment income that we derive from this portfolio. 
 

In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance:

   -- 
 Form 10-K for the year ended December 31, 2023; 
 
 
   -- 
 Form 10-Qs for the quarters ended March 31, 2024, June 30, 2024, and 
      September 30, 2024; and 
 
 
   -- 
 Form 8-Ks filed during 2024 and 2025. 
 

About Humana

Humana Inc. is committed to putting health first -- for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health -- delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211538257/en/

 
    CONTACT:    Lisa Stoner 

Humana Investor Relations

(502) 580-2652

e-mail: LStamper@humana.com

Mark Taylor

Humana Corporate Communications

(317) 753-0345

e-mail: MTaylor108@humana.com

(END) Dow Jones Newswires

February 11, 2025 06:30 ET (11:30 GMT)